52 North Health Raises £3.6M to Detect Deadly Sepsis in Cancer Patients Before It Becomes Fatal

52 North Health, a Cambridge-based medical device company, has raised £3.6 million from a syndicate of healthcare-focused investors including Cambridge Enterprise Ventures, Cancer Research Horizons, Cedars-Sinai Medical Center, Macmillan Innovation Impact, and Meridian Health Ventures. The company is developing a device to detect neutropenic sepsis in patients undergoing chemotherapy — one of the most dangerous and underdiagnosed complications of cancer treatment — at a stage early enough to allow clinical intervention before the condition becomes life-threatening.

Neutropenic sepsis arises when chemotherapy suppresses the immune system so severely that normal white blood cell counts drop to dangerously low levels, leaving patients unable to fight infection. When an infection takes hold in this state, it can progress to sepsis with extraordinary speed, and without early detection, to septic shock and death within hours. It is estimated that up to one in three cancer patients receiving chemotherapy will develop febrile neutropenia, and that neutropenic sepsis accounts for a significant proportion of deaths during active cancer treatment — deaths that occur not from the cancer itself but from the side effects of treatment. Current detection relies on patients either recognising their own symptoms and seeking emergency care, or attending regular blood tests at clinical intervals that may not catch rapid deterioration in time.

52 North Health's device is designed to identify the biomarkers of impending neutropenic sepsis at the point of care — in a patient's home or community setting — and flag the risk to clinicians before a crisis develops. This would fundamentally change the risk management of chemotherapy: rather than waiting for a patient to present at A&E with a developing sepsis, clinical teams could act on early warning signals and intervene with antibiotics or hospital admission at a window when the outcome is significantly better. The investor syndicate reflects the clinical seriousness of the problem: Cancer Research Horizons is the commercialisation arm of Cancer Research UK; Macmillan Innovation Impact is the innovation investment function of Macmillan Cancer Support; and Cedars-Sinai Medical Center is one of the most prominent academic medical centres in the United States, giving 52 North direct access to clinical expertise and potential US commercial pathways.

The funding will enable 52 North Health to advance its device through further development and clinical validation, building the evidence base required for regulatory clearance and NHS adoption. The company's investor base includes backing from across the cancer research and care ecosystem, signalling strong alignment between clinical need and commercial backing in addressing one of the most preventable sources of cancer treatment mortality.

Sources

• Crunchbase — 52 North Health company profile